Tactile Systems Tech Azioni (NASDAQ: TCMD)

Ultime notizie per Tactile Systems Tech (NASDAQ:TCMD) Azioni

Tactile Systems Tech

Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.

Tactile Systems Technology, Inc. - Common Stock

Tactile Systems Technology Inc

B of A Securities analyst Chase Mulvehill downgrades Atlas Energy Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AESI#NYSE">AESI</a>) from Buy to Neutral and maintains the price target from $22.5 to $22.5.

News

Downgrades

Price Target

Analyst Ratings

AESI

B of A Securities Downgrades Atlas Energy Solutions to Neutral, Maintains Price Target to $22.5

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Arcutis Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) with a Buy and maintains $19 price target.

Reiteration

ARQT

HC Wainwright & Co. Reiterates Buy on Arcutis Biotherapeutics, Maintains $19 Price Target

The Mosaic Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>) and Fosfatados Centro SPE Ltda (‘Fosfatados Centro') announced today that they have entered into an agreement for the sale of a phosphate asset owned by Mosaic located in Patos de Minas, Brazil. Upon the closing of the transaction, Fosfatados Centro will assume responsibility for the Patos de Minas mine and tailings dams and pay Mosaic $125 million (USD) in cash over six years. The transaction is subject to regulatory approvals, including approval by the Brazilian Administrative Council for Economic Defense (CADE), and other conditions precedents.

Asset Sales

Mosaic Sells Brazilian Phosphate Asset to Fosfatados Centro for $125M, Pending Regulatory Approval

<ul>
<li>Net Sales Increased 6.8% Compared to the Fourth Quarter of 2023, with U.S. Net Sales up 21.6%</li>
<li>Raised Adjusted EBITDA1 Guidance to be Between $6.0 million and $6.2 Million in the Fourth Quarter</li>
</ul>

Small Business

a.k.a. Brands Reports Preliminary 2024 Revenue Of $574.7M (+5.2% YoY), And Q4 $159M (+6.8% YoY); Expects Adjusted EBITDA Between $23M-$23.2M For 2024

SMX (Security Matters) Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMXWW#NASDAQ">SMXWW</a>) (the "Company"), today announced that the reverse stock split of the Company's ordinary shares, which was previously approved by the Company's shareholders on December 10, 2024, will begin trading on an adjusted basis giving effect to the reverse stock split on January 15, 2025 under the existing ticker symbol "SMX". The new CUSIP number of the Company's ordinary shares will be G8267K 158 and the new ISIN code will be IE000WZ90ZV5.
In accordance with the proposal approved by the Company's shareholders and the Board of Directors' subsequent determination to fix the split ratio at 28.5:1, every twenty-eight and one-half (28.5) ordinary shares of the Company will be automatically combined into one (1) ordinary share. This will reduce the number of outstanding ordinary shares of the Company from approximately 33 million to approximately 1 million.

Stock Split

SMXWW

SMX Announces 28.5:1 Reverse Stock Split, Adjusted Trading to Begin January 15, 2025

HC Wainwright &amp; Co. analyst Heiko Ihle maintains NioCorp Developments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NB#NASDAQ">NB</a>) with a Buy and lowers the price target from $8.5 to $3.25.

HC Wainwright & Co. Maintains Buy on NioCorp Developments, Lowers Price Target to $3.25

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.clearwateranalytics.com%2F%3Futm_medium%3Dthird-party%26utm_source%3Dpress-release%26utm_campaign%3Dbw-enfusion&amp;esheet=54178021&amp;newsitemid=20250113430675&amp;lan=en-US&amp;anchor=Clearwater+Analytics&amp;index=1&amp;md5=d504209e354f2352d1385093fd4f42bb">Clearwater Analytics</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NYSE">CWAN</a>) ("Clearwater") and Enfusion, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENFN#NYSE">ENFN</a>) ("Enfusion") today announced their entry into a definitive merger agreement for Clearwater to acquire Enfusion, a leader in software-as-a-service (SaaS) solutions for the investment management and hedge fund industry. The purchase price is $11.25 per share, delivered in an approximately equal mix of cash and stock. Additionally, Clearwater will pay $30 million to terminate Enfusion's tax receivable agreement (TRA). This equates to a purchase price of approximately $1.5 billion.

CWAN

ENFN

Clearwater Analytics to Acquire Enfusion for $1.5B in Cash and Stock Deal

SuperCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPCB#NASDAQ">SPCB</a>), a global provider of secure solutions for the e-Government, IoT, and Cybersecurity sectors, announced today that it has secured a new electronic monitoring (EM) contract with a Juvenile Probation Agency in Ohio. This contract marks SuperCom's first project with a government agency in Ohio and its entry into its sixth new U.S. state since the summer of 2024, highlighting SuperCom's expansion momentum in providing innovative public safety solutions nationwide. This contract also marks the 20th new EM contract in the U.S. since the summer of 2024.
&nbsp;
The project in Ohio will include SuperCom's innovative PureOne technology, which provides real-time GPS tracking, secure communication, and advanced compliance capabilities. The discreet PureOne device, designed with a humane approach, helps participants avoid stigma while remaining integrated into society and continuing their rehabilitation journey. These cutting-edge solutions are tailored specifically for correctional and juvenile programs, enhancing public safety while promoting reintegration and operational efficiency.

SPCB

SuperCom Expands to Ohio, Secures Juvenile Probation EM Contract with Innovative PureOne Technology

Needham analyst Scott Berg reiterates ServiceTitan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) with a Buy and maintains $125 price target.

TTAN

Needham Reiterates Buy on ServiceTitan, Maintains $125 Price Target

<ul>
<li>100% (9/9) of treated evaluable subjects demonstrated improvement or preservation in visual function compared to untreated eyes at both one and two years</li>
<li>100% (9/9) of treated evaluable subjects demonstrated improvement or stabilization in mobility testing, which was only performed up to one year</li>
<li>Improvement in visual function was statistically significant (p=0.01, treated vs untreated eyes), regardless of mutation at two years</li>
<li>Favorable long-term safety and tolerability profile with no serious adverse events related to OCU400</li>
</ul>

OCGN

Ocugen Reveals Two-Year Results From Phase 1/2 Trial Of OCU400, An Innovative Modifier Gene Therapy For Retinitis Pigmentosa

Preliminary Fourth Quarter and Full Year 2024 Financial Results&#x2A; and Recent Business Highlights
<ul>
<li>Preliminary fourth quarter and full-year 2024 U.S. net product revenue for OGSIVEO were $61.5 million and $172.0 million, respectively.</li>
<li>As of December 31, 2024, total preliminary cash, cash equivalents, and marketable securities was $461.9 million. SpringWorks expects its cash position to fund operations through profitability, which the Company anticipates achieving in the first half of 2026.</li>
<li>Presented long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with progressing desmoid tumors in the fourth quarter of 2024. These results showed that longer-term treatment with nirogacestat (median duration of treatment: 34 months) was associated with further reductions in tumor size, increase in objective response rate with additional partial responses and complete responses, sustained improvements in desmoid tumor symptoms including pain, and a consistent safety profile.</li>
<li>Obtained an exclusive, global license from Rappta Therapeutics Oy for a first-in-class molecular glue of specific Protein Phosphatase 2A (PP2A) complexes. PP2A mutations represent a class of targetable oncogenic drivers in molecularly defined subsets of uterine cancer patients with high unmet need. In preclinical models of PP2A mutant uterine cancer, SW-3431 (formerly RPT04402) showed rapid, deep and durable tumor regressions as a monotherapy. In exchange for the license, Rappta received a $13 million upfront payment and is eligible to receive further clinical, regulatory and commercial milestone payments, and tiered single digit royalties on net sales.</li>
</ul>

Earnings

SWTX

SpringWorks Therapeutics Reported Q4 OGSIVEO Revenue Of $61.5M, Cash Balance Of $461.9M

Johnson &amp; Johnson expects to fund the transaction through a combination of cash on hand and debt. Johnson &amp; Johnson expects to maintain a strong balance sheet and to continue to support its stated capital allocation priorities of R&amp;D investment, competitive dividends, value-creating acquisitions, and strategic share repurchases.
Johnson &amp; Johnson will provide commentary on any potential impact to Adjusted Earnings Per Share (EPS) from the transaction when it provides its initial full year 2025 guidance during the fourth quarter earnings call on Wednesday, January 22, 2025.
 &nbsp;

ITCI

Johnson & Johnson Says Intra-Cellular Acquisition Includes CAPLYTA (Lumateperone), The First And Only US FDA-Approved Treatment For Bipolar I And II Depression As An Adjunctive And Monotherapy

WIIM

Intra-Cellular Therapies shares are trading sharply higher after Johnson & Johnson agreed to acquire the company for $132.00 per share in cash.

LULU

Lululemon shares are trading higher after the company raised its Q4 guidance

lululemon athletica inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) today announced that, for the fourth quarter of fiscal 2024, the Company now expects net revenue will be in the range of $3.560 billion to $3.580 billion, representing growth of 11% to 12% compared to the fourth quarter of fiscal 2023, or growth of 6% to 7% excluding the 53rd week of 2024. The previous guidance range was $3.475 billion to $3.510 billion.
Diluted earnings per share are now expected to be in the range of $5.81 to $5.85 for the fourth quarter of fiscal 2024 compared to the Company's previous guidance range of $5.56 to $5.64.
The Company now expects gross margin to increase approximately 30 basis points relative to the fourth quarter of fiscal 2023, compared to its previous guidance of a decrease of 20 to 30 basis points. It now expects deleverage of selling, general, and administrative expenses of 80 to 90 basis points relative to the fourth quarter of fiscal 2023 compared to its previous guidance of deleverage of 90 to 100 basis points. There is no change to the Company's previous guidance for the effective tax rate.

Guidance

Lululemon Athletica Expects Q4 Revenue Of $3.56B-$3.58B (Prior $3.475B-$3.510B) Vs $3.517B Est, EPS Of $5.81-$5.85 (Prior $5.56-$5.64) Vs $5.66 Est

U.S. stock futures declined on Monday following Friday&#8217;s steep fall. Futures of all four major indices fell in premarket trade.
Friday&#8217;s decline followed a strong upmove in yields as the economy added 256,000 jobs in December, much above the economists&#8217; forecast of 165,000 jobs, the strongest since May 2024.
Traders now await the consumer price inflation data this week on Wednesday, which will further clear the case for the Fed to pause the rate cuts.
The 10-year and two-year Treasury notes yielded 4.78% and 4.42%, respectively. The probability of having no change in the interest rates for the upcoming Jan. 31, 2025 decision was at 97.3%, according to CME Group&#8217;s FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-1.27%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.86%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.38%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.21%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Monday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was down 0.76% to $576.10&nbsp;and the Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) dropped 1.16% to $501.35, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From The Last Session
Wall Street suffered significant losses last week, erasing all gains since the election. This was primarily driven by a robust jobs report, which increased concerns about persistent inflation and further interest rate hikes by the Federal Reserve. The week&#8217;s trading was also impacted by rising geopolitical tensions and increased inflation expectations.
The session witnessed considerable losses among growth equities, particularly those with high valuations and exposure to interest rate sensitivity. This included semiconductor companies such as Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), as well as technology firms like Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>).
The Dow Jones Industrial Average closed 1.63% lower at 41,938.45, down approximately 697 points. The S&amp;P 500 Index fell 1.54% to 5,827.04, while the Nasdaq Composite dipped 1.63% to 19,161.63. Russell 200, on the other hand, fell 2.22% to 2,189.23.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-1.63%</td>
<td>19,161.63</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-1.54%</td>
<td>5,827.04</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-1.63%</td>
<td>41,938.45</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-2.22%</td>
<td>2,189.23</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
On <a href="https://www.benzinga.com/25/01/42939374/as-bond-yields-near-the-crucial-5-mark-last-seen-briefly-in-2023-and-global-financial-crisis-this-analyst-says-market-appears-to-be-overreacting">Friday</a>, the U.S. 30-year Treasury yielded 4.950% by the end of the trading session, however, it touched a high of 5.005% intraday. The 10-year Treasury, on the other hand, yielded an intraday high of 4.790% to settle at 4.762% on Friday.
&#8220;It is most likely that the pressure on interest rates is being driven by inflation fears from the soon-to-be-announced tariffs that Trump 2.0 will bring.&#8221; said Louis Navellier, the chairman and founder of Navellier &amp; Associates. &#8220;The market appears to be overreacting,&#8221; he added.
Ed Yardeni and Eric Wallerstein in their note called &#8216;Bond Vigilantes Spoking Stock Jockey&#8217; said, &#8220;If Tuesday&#8217;s CPI inflation rate for December is higher than expected, causing the 10-year Treasury bond yield to revisit 2023&#8217;s high of 5.00%.&#8221;
As the stocks struggled after Friday&#8217;s reports and bond yields&#8217; reaction, Yardeni and Navellier said that this dip was a buying opportunity.
Navellier said that the market could be additionally reacting to the uncertainty on what the Fed may do. Stocks, however, are taking the higher yields to heart, he added, saying &#8220;There&#8217;s no reason to panic.&#8221; as the pullback on higher rates is likely a &#8220;buying opportunity unless earnings disappoint.&#8221;
Yardeni also reiterated its forecast of 7,000 points on the S&amp;P 500 by the end of the year. &#8220;We still believe that the 10-year Treasury bond yield should trade mostly between 4.25% and 4.75% this year. So we think that the selloffs in the stock and bond markets are buying opportunities.&#8221;
Carson Research&#8217;s VP and global macro strategist, Sonu Varghese in a blog post said that it's not useful to read too much into market moves, especially short-term ones.
He argues that the interest rates are higher because the market likely thinks stronger job creation and economy, will put more upward pressure on inflation, which means the Federal Reserve will have to pause on rate cuts. &#8220;Markets are now expecting just one rate cut in 2025 (with a probability of under 25% for a second one) and don't expect it to happen before June,&#8217; he added.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
<ul>
<li>On Monday, the data for December&#8217;s monthly U.S. federal budget will be released at 2:00 p.m., ET.</li>
</ul>
<ul>
<li>On Tuesday, NFIB optimism index for December will be released at 6:00 a.m., ET.</li>
</ul>
<ul>
<li>December&#8217;s headline and core producer price index data will be announced at 8:30 a.m., ET.</li>
</ul>
<ul>
<li>Kansas City Fed President Jeffrey Schmid will be speaking at 10:00 a.m. ET.</li>
</ul>
<ul>
<li>Fed will release its Beige Book at 2:00 p.m., ET.</li>
</ul>
<ul>
<li>New York Fed President Williams will deliver his opening remarks on the policy at 3:05 p.m., ET.</li>
</ul>
<ul>
<li>On Wednesday, the headline and core consumer price index for December and the Empire State manufacturing survey data for January will be announced at 8:30 a.m., ET.</li>
</ul>
<ul>
<li> Richmond Fed President Barkin will speak at 9:00 a.m., ET.</li>
</ul>
<ul>
<li>New York Fed President Williams will speak at 11:00 a.m., ET.</li>
</ul>
<ul>
<li>Chicago Fed President Goolsbee will speak at 12:00 p.m., ET.</li>
</ul>
<ul>
<li>On Thursday, initial jobless claims till Jan. 11 will be released at 8:30 a.m., ET.</li>
</ul>
<ul>
<li>December&#8217;s U.S. retail sales, import price index and Philadelphia Fed manufacturing survey will be announced at 8:30 a.m., ET.</li>
</ul>
<ul>
<li>Business inventory data for November and the Home builder confidence index for January will be released at 10:00 a.m., ET.</li>
</ul>
<ul>
<li>On Friday, housing starts and building permits data for December will be released at 8:30 a.m., ET.</li>
</ul>
<ul>
<li>The industrial production and capacity utilization for December will be announced at 9:15 a.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Comtech Telecommunications Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMTL#NASDAQ">CMTL</a>) was up 10.17% in premarket ahead of its earnings before the opening bell. Analysts expect a quarterly loss of 16 cents per share on revenue of $125.53 million.</li>
</ul>
<ul>
<li>WD-40 Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDFC#NASDAQ">WDFC</a>) was up 2.48% after it posted better-than-expected results for its first quarter and reiterated its FY25 guidance on Friday.</li>
</ul>
<ul>
<li>KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) was down 0.76% ahead of its earnings, which is slated to be reported after the market closes. Analysts expect quarterly earnings of $2.45 per share on revenue of $1.99 billion.</li>
</ul>
<ul>
<li>Nordstrom Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) was up 0.12% after the company said that its net sales rose 4.9%, while comparable sales increased 5.8% for the nine-week holiday period ended Jan. 4.</li>
</ul>
<ul>
<li>Rigetti Computing Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) was down 16.01%, Quantum Computing Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) declined 7.91%, D-Wave Quantum Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) slipped 14.21% and IONQ Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) fell 14.51% in premarket after CNBC&#8217;s Jim Cramer <a href="https://www.benzinga.com/markets/equities/25/01/42890014/jim-cramer-warns-on-quantum-stories-as-stocks-plunge-we-need-you-out-before-the-froth-goes-away">highlighted</a> the speculative nature of nuclear and quantum computing stocks and advised investors to be cautious and realistic about the potential for short-term gains. </li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were higher in the early New York session by 1.76% to hover around $77.08 per barrel.
The gold spot index was down by 0.36% to $2,705.01 per ounce. The Dollar Index was up 0.34% at the 110.02 level.
Asian markets closed lower on Monday as Hong Kong&#8217;s Hang Seng, Japan&#8217;s Nikkei 225, India&#8217;s S&amp;P BSE Sensex, China&#8217;s CSI 300, Australia&#8217;s ASX 200, and South Korea&#8217;s Kospi index declined. European markets were also trading lower.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/01/42938954/michael-saylors-microstrategy-faces-risk-if-mstrs-0-convertible-bond-lenders-recall-non-recourse-loans-due-to-covenant-breach-heres-what-it-means-for-investors">Michael Saylor&#8217;s MicroStrategy Faces Risk If MSTR&#8217;s 0% Convertible Bond Lenders Recall Non-Recourse Loans Due To Covenant Breach: Here&#8217;s What It Means For Investors </a></li>
</ul>
Image Via Shutterstock

Analyst Color

Equities

Market Summary

Broad U.S. Equity ETFs

Futures

Pre-Market Outlook

Markets

ETFs

General

ABTS

CMTL

IONQ

NVDA

PLTR

QBTS

QUBT

RGTI

WDFC

US Stock Futures Indicate Lower Opening On Monday After Last Week's Steep Fall: Analyst Says It's A 'Buying Opportunity,' But Market May Dip Further If This Happens

Johnson & Johnson Agrees To Acquire Intra-cellular Therapies For $132.00 Per Share In Cash For Total Equity Value Of $14.6B

Large Cap

Health Care

Johnson & Johnson Has Agreed To Acquire Intra-cellular Therapies For $132.00 Per Share In Cash For A Total Equity Value Of Approximately $14.6B

HC Wainwright &amp; Co. analyst Scott Buck reiterates SoundHound AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) with a Buy and maintains $26 price target.

SOUN

HC Wainwright & Co. Reiterates Buy on SoundHound AI, Maintains $26 Price Target

Citigroup analyst Andrew Kaplowitz reinstates Symbotic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) with a Buy and announces $37 price target.

Initiation

Citigroup Reinstates Buy on Symbotic, Announces $37 Price Target

Tactile Systems Technology GAAP EPS of $0.21 beats by $0.03, revenue of $73.09M misses by $2.92M

Tactile Systems Technology, Inc. (TCMD) Q3 2024 Earnings Call Transcript

Tactile Systems Technology ( ($TCMD) ) has released its Q3 earnings. Here is a breakdown of the information Tactile Systems Technology presented to...

Tactile Systems Technology Reports Q3 2024 Results, Launches Share Buyback

BTIG downgraded Tactile Systems (TCMD) to Neutral from Buy without a price target following the Q3 report. While the shares are inexpensive and Tac...

Tactile Systems downgraded to Neutral from Buy at BTIG

In a report released today, Adam Maeder from Piper Sandler maintained a Buy rating on Tactile Systems Technology (TCMD – Research Report), with a p...

Piper Sandler Sticks to Their Buy Rating for Tactile Systems Technology (TCMD)

Tactile Systems cut to Neutral at BTIG after Q3 revenue miss

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.&nbsp; 1. STOCK NEWS: Boeing's (BA) machinist union ha...

Boeing union to end strike, Palantir reports Q3 beat: Morning Buzz

The healthcare technology market is well-poised for long-term growth, thanks to the growing demand for medical devices, cutting-edge technologies, and changing patient care systems. Thus, it could be wise to buy fundamentally solid healthcare technology stocks Zimmer Biomet Holdings (ZBH), STERIS (STE), and Tactile Systems Technology (TCMD), which are revolutionizing patient care. Keep reading... The integration of AI in healthcare is continuously transforming the operations and processes of the medical field. Companies engaged in the healthcare industry are leveraging artificial intelligence (AI) to advance patients' care and lower costs propelling the medical technology market.
Given the industry's bright prospects, investors could consider investing in sound healthcare technology stocks Zimmer Biomet Holdings, Inc. (<a href="https://stocknews.com/stock/ZBH/">ZBH</a>), STERIS plc (<a href="https://stocknews.com/stock/STE/">STE</a>), and Tactile Systems Technology, Inc. (<a href="https://stocknews.com/stock/TCMD/">TCMD</a>), which are revolutionizing patient care.
The healthcare industry is undergoing rapid transformation owing to the pandemic, shifting demographics, rapid technological advancements, and rising patient expectations. As a result, healthcare companies are increasingly investing in and <a href="https://mobidev.biz/blog/technology-trends-healthcare-digital-transformation">adapting digital technologies</a> to maintain their competitive edge and offer the best solutions to patients.
Concrete technologies like telemedicine, AI-enabled medical devices, and blockchain electronic health records are <a href="https://www.digitalauthority.me/resources/state-of-digital-transformation-healthcare/">entirely reshaping healthcare processes and operations</a>. These modernized technologies, along with offering operational capabilities, also help companies reduce their costs, enhance operational efficiency, and mitigate other risks.
Blockchain technologies, AI, and the Internet of Things (IoT) have significantly impacted the healthcare sector along with emerging devices and infrastructures that are helping doctors, healthcare organizations, and patients gain immediate access to healthcare information, resulting in better decision-making and treatment options.
Fortune Business Insights projects the global healthcare IT market to grow to $981.23 billion by 2032, <a href="https://www.fortunebusinessinsights.com/healthcare-it-market-109359">exhibiting a CAGR of 15.4%</a>, driven by healthcare information technology opportunities like improving clinical outcomes, reducing human error, improving practice efficiencies, and facilitating care coordination.
Given these favorable market trends, let's look at the fundamentals of the top three <a href="https://stocknews.com/category/medical-devices-equipment/">Medical – Devices &amp; Equipment</a> stocks, starting with the third choice.
Stock #3: Zimmer Biomet Holdings, Inc. (<a href="https://stocknews.com/stock/ZBH/">ZBH</a>)
ZBH operates as a medical technology company globally. It designs, manufactures, and markets orthopedic reconstructive products, like knee and hip products, S.E.T. products, and craniomaxillofacial and thoracic products. It also offers robotic, surgical, and bone cement products.
On November 25, ZBH announced U.S. FDA Premarket Approval Application (PMA) supplement approval for the Oxford&#xAE; Cementless Partial Knee. The partial knee allows surgeons to perform a PKR with improved fixation, better long-term implant survival rate, and improved efficiency in the operating room compared to the Oxford cemented partial knee procedure.
The Oxford cementless partial knee is now the only FDA-approved cementless partial knee implant in the U.S. This marked a revolutionary step offering patients a better range of motion, a more natural feel, and a more stable implant-to-bone fixation.
Also, on November 18, ZBH received the CE Mark certification for its Persona&#xAE; revision knee system. The addition to the Persona segment instills ZBH's commitment to personalized solutions, offering surgeons advanced tools for revision knee arthroplasty.
For the third quarter of 2024, which ended September 30, ZBH's total revenues increased 4% year-over-year to $1.82 billion. The company's adjusted <a href="https://www.investopedia.com/terms/o/operating_profit.asp">operating profit</a> grew 3.5% from the year-ago value to $480.20 million. Adjusted net earnings of ZBH amounted to $353.20 million or $1.74 per common share, up 1.9% and 5.5% year-over-year, respectively.
In addition, the company's free cash flow rose 64.3% from the prior year's quarter to $310 million.
According to the company's updated guidance for fiscal 2024, ZBH projects reported revenue change between 3.5% and 4%. It also expects adjusted EPS in the $7.95 - $8.05 range.
Street expects ZBH's revenue and EPS for the fourth quarter (ending December 2024) to increase 3.9% and 4.3% year-over-year to $2.02 billion and $2.30, respectively. Moreover, the company topped the consensus revenue and EPS estimates in all four trailing quarters, which is impressive.
ZBH's stock has increased 7.7% over the past month to close the last trading session at $112.02.
ZBH's bright prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
The stock has a B grade for Growth, Value, and Quality. Within the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical – Devices &amp; Equipment</a> industry, ZBH is ranked #26 out of 138 stocks.
<a href="https://stocknews.com/stock/ZBH/">Click here</a> to access additional ratings of ZBH for Momentum, Sentiment, and Stability.
Stock #2: STERIS plc (<a href="https://stocknews.com/stock/STE/">STE</a>)
STE offers infection prevention products and services worldwide. The company operates in three segments: Healthcare; Applied Sterilization Technologies (AST); and Life Sciences. The company offers cleaning chemistries and sterility assurance products, automated endoscope reprocessing systems and tracking products, endoscopy accessories, and other equipment.
On October 30, STE declared the distribution of a quarterly interim dividend of $0.57 per share. The dividend is to be paid on December 19, 2024, to shareholders of record at the close of business on November 19, 2024.
With 14 years of consecutive dividend growth, STE pays an annual dividend of $2.28, which translates to a yield of 1.06% at the current share price. Its four-year average dividend yield is 0.86%. And the company's dividend payouts have increased at a 9.5% CAGR over the past three years.
STE's total revenues increased 7.3% year-over-year to $1.33 billion for the third quarter that ended September 30, 2024. The company's gross profit grew 6% from the year-ago value to $578.79 million. Net income attributable to stockholders came in at $150.03 million and $1.51 per share, indicating growth of 30.1% and 30.2% year-over-year, respectively.
Analysts expect STE's revenue for the first quarter (ending June 2025) to grow 6.5% year-over-year to $1.36 billion. For the same quarter, its EPS is expected to increase 12.5% year-over-year to $2.28. Furthermore, the company surpassed the consensus EPS estimates in each of the trailing four quarters.
STE's shares have gained 8% over the past year to close the last trading session at $217.47.
STE's sound fundamentals are reflected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
The stock has a B grade for Stability and Sentiment. Within the Medical – Devices &amp; Equipment industry, STE is ranked #12 out of 138 stocks.
In addition to the POWR Ratings we've stated above, we also have STE ratings for Value, Growth, Quality, and Momentum. Get all STE ratings <a href="https://stocknews.com/stock/STE/">here</a>.
Stock #1: Tactile Systems Technology, Inc. (<a href="https://stocknews.com/stock/TCMD/">TCMD</a>)
TCMD is a medical technology company that develops and provides medical devices to treat underserved chronic diseases. The company offers Flexitouch Plus system and Entre Plus System. It also has a mobile application, Kylee, which helps patients learn about lymphedema.
On October 2, TCMD launched Nimbl&#x2122;, its next-generation pneumatic compression platform for the treatment of upper extremity lymphedema. Nimbl is significantly smaller and lighter than previous device iterations and is indicated for treating patients with both upper and lower extremity lymphedema, chronic edema, venous insufficiency, and wound healing.
This important portfolio addition reflects TCMD's commitment to advancing solutions that increase patient access to therapy with a differentiated user experience.
TCMD reported total revenue of $73.09 million, up 5% year-over-year during the third quarter that ended June 30, 2024, and its non-GAAP gross profit grew 10.9% from the year-ago value to $55.10 million. The company's adjusted EBITDA of $10.72 million indicates a growth of 39.3% from the prior year's quarter.
Furthermore, the company's net income came in at $5.16 million and $0.21 per common share for the quarter, respectively.
Street expects TCMD's revenue for the second quarter (ending June 2025) to increase 9.2% year-over-year to $79.95 million, and its EPS for the same period is expected to grow 16.6% year-over-year to $0.23. Also, the company has topped the consensus EPS estimate in three of the trailing four quarters.
Shares of TCMD have surged 49.3% over the past six months and 34.9% over the past year to close the last trading session at $18.93.
TCMD's POWR Ratings reflect its sound fundamentals. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
TCMD has an A grade for Value and a B for Quality. The stock is ranked #6 among the 138 stocks in the same industry.
In addition to the POWR Ratings we've stated above, we also have TCMD ratings for Growth, Sentiment, Momentum, and Stability. Get all TCMD ratings <a href="https://stocknews.com/stock/TCMD/">here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
ZBH shares were trading at $112.02 per share on Thursday morning, up $1.38 (+1.25%). Year-to-date, ZBH has declined -7.37%, versus a 27.18% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/zbh-ste-tcmd-3-healthcare-technology-companies-revolutionizing-patient-care/>3 Healthcare Technology Companies Revolutionizing Patient Care</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Healthcare Technology Companies Revolutionizing Patient Care

Virtual Meeting to be held on December 10 hosted by B. Riley. Published first on TheFly – the ultimate source for real-time, market-moving breaking...

Tactile Systems management to meet virtually with B. Riley

Tactile Systems Technology: A First Look

AAPL

ALAB

AZPN

BWIN

CRRFY

CVNA

DLTR

EBAY

EGHT

JELD

NFLX

NXPI

PAYO

QNST

REAL

SLAB

TCMD

UBER

VMEO

Press Releases

Tactile Systems Technology, Inc. Reports First Quarter 2024 Financial Results

Tactile Medical to Present at the William Blair 44th Annual Growth Stock Conference

Tactile Medical to Release Second Quarter of Fiscal Year 2024 Financial Results on August 5, 2024

Tactile Systems Technology, Inc. Reports Second Quarter 2024 Financial Results

Tactile Medical Receives PDAC Approval for Nimbl™ Lymphedema Platform

Tactile Medical Announces Positive Clinical Trial Results in Lymphedema Patients Using Advanced Pneumatic Compression Device Therapy

Tactile Medical Launches Next-Generation Nimbl™ Lymphedema Platform

Tactile Medical to Release Third Quarter of Fiscal Year 2024 Financial Results on November 4, 2024

Tactile Systems Technology, Inc. Reports Third Quarter 2024 Financial Results

Tactile Medical to Present at the Piper Sandler 36th Annual Healthcare Conference

Comments

Tactile Systems Tech

Notizie

Ultime notizie per Tactile Systems Tech (NASDAQ:TCMD) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO